Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) kicked off on Tuesday, down -6.44% from the previous trading day, before settling in for the closing price of $13.98. Over the past 52 weeks, ARWR has traded in a range of $9.57-$30.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.87% over the past five years. While this was happening, its average annual earnings per share was recorded 41.08%. With a float of $114.31 million, this company’s outstanding shares have now reached $125.57 million.
Let’s look at the performance matrix of the company that is accounted for 609 employees. In terms of profitability, gross margin is -481.68%, operating margin of -25037.88%, and the pretax margin is -25955.44%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc is 16.75%, while institutional ownership is 73.84%. The most recent insider transaction that took place on Apr 11 ’25, was worth 583,692. In this transaction Chief Executive Officer of this company sold 50,800 shares at a rate of $11.49, taking the stock ownership to the 3,921,255 shares. Before that another transaction happened on Apr 10 ’25, when Company’s Chief Executive Officer sold 50,000 for $10.87, making the entire transaction worth $543,500. This insider now owns 3,972,055 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.08% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Take a look at Arrowhead Pharmaceuticals Inc’s (ARWR) current performance indicators. Last quarter, stock had a quick ratio of 6.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 718.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.15, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -3.69 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) saw its 5-day average volume 1.49 million, a negative change from its year-to-date volume of 1.94 million. As of the previous 9 days, the stock’s Stochastic %D was 49.98%. Additionally, its Average True Range was 0.95.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 23.91%, which indicates a significant decrease from 53.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.45% in the past 14 days, which was higher than the 69.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $19.66. Nevertheless, the first resistance level for the watch stands at $13.71 in the near term. At $14.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.78. If the price goes on to break the first support level at $12.64, it is likely to go to the next support level at $12.20. Assuming the price breaks the second support level, the third support level stands at $11.57.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
The company with the Market Capitalisation of 1.80 billion has total of 137,317K Shares Outstanding. Its annual sales at the moment are 3,550 K in contrast with the sum of -599,490 K annual income. Company’s last quarter sales were recorded 2,500 K and last quarter income was -173,090 K.
